Fractional Laser Therapy and Dermabrasion for Scar Revision

NCT ID: NCT01409863

Last Updated: 2023-10-04

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-03-31
• Study Completion Date: 2010-03-31

Brief Summary

The goals of this study will be to compare the safety and efficacy of fractional photothermolysis (Fraxel) with dermabrasion when used for scar revision.

Detailed Description

Post traumatic and post surgical scar resurfacing is a common reason for patient visits to dermatologists and plastic surgeons. The Fraxel Laser is a new FDA cleared treatment for textural irregularities of the skin. There have been no studies examining the efficacy of Fraxel specifically for scar resurfacing though it is being used in clinical practice as its clearance was given under hte umbrella of "coagulation of soft tissue." Dermabrasion is the gold standard for scar resurfacing and provides the criterion against which Fraxel therapy should be measured.

Conditions

Scar

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

laser and standard diamond fraise dermabrasion

laser and standard diamond fraise dermabrasion

Group Type: NO_INTERVENTION

laser and standard diamond fraise dermabrasion

Intervention Type: PROCEDURE

standard dermabrasion, CO2 laser resurfacing

Interventions

laser and standard diamond fraise dermabrasion

standard dermabrasion, CO2 laser resurfacing

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• post surgical or post traumatic scar on face or scalp
• age 18 or older
• able to read and comprehend English
• Willing to follow treatment schedule and post treatment care requirements
• signed informed consent form
• Fitzpatrick skin type I-III

Exclusion Criteria

• known photosensitivity
• taken any medications known to induce photosensitivity in previous three months
• taken accutane within past 12 months
• pregnant or nursing
• currently on topical or oral antibiotics
• immunocompromised status
• skin type IV or greater

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Minnesota

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

John Christophel, MD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Other Identifiers

1001M75732

Identifier Type: -

Identifier Source: org_study_id